WO2007026224A3 - 5-ht1b antagonist composition for depression, anxiety and cognition - Google Patents

5-ht1b antagonist composition for depression, anxiety and cognition Download PDF

Info

Publication number
WO2007026224A3
WO2007026224A3 PCT/IB2006/002377 IB2006002377W WO2007026224A3 WO 2007026224 A3 WO2007026224 A3 WO 2007026224A3 IB 2006002377 W IB2006002377 W IB 2006002377W WO 2007026224 A3 WO2007026224 A3 WO 2007026224A3
Authority
WO
WIPO (PCT)
Prior art keywords
cognition
anxiety
depression
antagonist composition
formula
Prior art date
Application number
PCT/IB2006/002377
Other languages
French (fr)
Other versions
WO2007026224A2 (en
Inventor
Susan Beth Sobolov-Jaynes
Christopher John Helal
Harry Ralph Howard Jr
Original Assignee
Pfizer Prod Inc
Susan Beth Sobolov-Jaynes
Christopher John Helal
Harry Ralph Howard Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Susan Beth Sobolov-Jaynes, Christopher John Helal, Harry Ralph Howard Jr filed Critical Pfizer Prod Inc
Publication of WO2007026224A2 publication Critical patent/WO2007026224A2/en
Publication of WO2007026224A3 publication Critical patent/WO2007026224A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to pharmaceutical compositions comprising benzyl(idene)-lactam derivatives of formula (I) wherein R1 is a group of the formula (G1) or (G2) depicted below, and a pharmaceutically acceptable salt or optical isomer thereof and at least one active agent selected from (a) a selective serotonin re-uptake inhibitor (SSRl), (b) an alpha-2-delta (A2D) ligand or (c) a corticotropin releasing factor (CRF) antagonist and optionally a pharmaceutically acceptable carrier.
PCT/IB2006/002377 2005-08-31 2006-08-21 5-ht1b antagonist composition for depression, anxiety and cognition WO2007026224A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71292805P 2005-08-31 2005-08-31
US60/712,928 2005-08-31

Publications (2)

Publication Number Publication Date
WO2007026224A2 WO2007026224A2 (en) 2007-03-08
WO2007026224A3 true WO2007026224A3 (en) 2007-12-21

Family

ID=37591532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002377 WO2007026224A2 (en) 2005-08-31 2006-08-21 5-ht1b antagonist composition for depression, anxiety and cognition

Country Status (4)

Country Link
JP (1) JP2007063278A (en)
AR (1) AR056480A1 (en)
TW (1) TW200744599A (en)
WO (1) WO2007026224A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN106061964B (en) * 2014-01-20 2019-10-25 豪夫迈·罗氏有限公司 Neurogenetic N- phenyl-lactam derivatives and its purposes in the treatment of neuropathic conditions can be stimulated
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036867A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
EP1113015A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
US6380186B1 (en) * 1996-09-30 2002-04-30 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
WO2006075226A1 (en) * 2005-01-13 2006-07-20 Pfizer Products Inc. 11c-labeled benzyl-lactam compounds and their use as imaging agents
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036867A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
US6380186B1 (en) * 1996-09-30 2002-04-30 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
EP1113015A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
WO2006075226A1 (en) * 2005-01-13 2006-07-20 Pfizer Products Inc. 11c-labeled benzyl-lactam compounds and their use as imaging agents
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIDSON C ET AL: "SYNERGISM OF 5-HT 1B/D ANTAGONIST WITH PAROXETINE ON SEROTONIN EFFLUX IN RAT VENTRAL LATERAL GENICULATE NUCLEUS SLICES", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 43, no. 4, 1997, pages 405 - 409, XP000918530, ISSN: 0361-9230 *
DAWSON L A ET AL: "THE ROLE OF 5-HT1A AND 5-HT1B/1D RECEPTORS ON THE MODULATION OF ACUTE FLUOXETINE-INDUCED CHANGES IN EXTRACELLULAR 5-HT: THE MECHANISM OF ACTION OF (PLUS OR MINUS)PINDOLOL", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 6, 2000, pages 1044 - 1052, XP001199433, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
JP2007063278A (en) 2007-03-15
AR056480A1 (en) 2007-10-10
WO2007026224A2 (en) 2007-03-08
TW200744599A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
WO2006066133A3 (en) Histone deacetylase inhibitors
EA200970585A1 (en) BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2006049835A3 (en) Indole and benzimidazole derivatives
EA201001086A1 (en) THE COMPOSITION OF PELLETS OF THE PROLONGED SURVENT, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, THE WAY OF ITS MANUFACTURE AND ITS APPLICATION
MA28338A1 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES
RS52169B (en) Stable laquinimod preparations
WO2008013838A3 (en) Pyridizinone derivatives
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
ATE479687T1 (en) KINASE INHIBITORS
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
DK1569899T3 (en) Substituted 3-alkyl and 3-arylalkyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
EA201100795A1 (en) PHARMACEUTICAL COMPOSITION OF EFFICIENT HSG INHIBITOR FOR ORAL ADMINISTRATION
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
DK1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
WO2005117895A3 (en) Compositions comprising meloxicam
SE0400284D0 (en) Novel compounds
NO20065719L (en) Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor.
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
IL188438A (en) Pharmacologically active benzofused five-membered heterocycles, or pharmaceutically acceptable salts and esters thereof and pharmaceutical compositions containing them and their use as inhibitors of catechol-o-methyltransferase (comt) enzyme
WO2009078481A1 (en) Bicyclic heterocyclic derivative
WO2007026224A3 (en) 5-ht1b antagonist composition for depression, anxiety and cognition
WO2009060952A1 (en) Novel preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808824

Country of ref document: EP

Kind code of ref document: A2